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Cancer treatmentIt is 40 years since cancer growth was correlated with neovascularisation. Anti-angiogenic drugs
remain at the forefront of cancer investigations but progress has been disappointing and unex-
pected toxicities are emerging. Gap junction channels are implicated in lesion spread following
injury, with channel blockers shown to improve healing; in particular preventing vascular disrup-
tion and/or restoring vascular integrity. Here we brieﬂy review connexin roles in vascular leak
and endothelial cell death that occurs following acute wounds and during chronic disease, and
how connexin channel regulation has been used to ameliorate vascular disruption. We then review
chronic inﬂammatory disorders and trauma in the eye, concluding that vascular disruption under
these conditions mimics that seen in tumours, and can be prevented with connexin hemichannel
modulation. We apply this knowledge to tumour vessel biology, proposing that contrary to current
opinion, these data suggest a need to protect, maintain and/or restore cancer vasculature. This may
lead to reduced tumour hypoxia, promote the survival of normal cells, and enable improved thera-
peutic delivery or more effective radiation therapy.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
It is now over 40 years since Judah Folkman [1] reported that
the growth of solid neoplasms, that account for over 85% of cancer
mortality, is always accompanied by neovascularisation. This con-
cept remains fundamental to approaches in cancer research [see
for example 2, 3] with HIF-1a in particular associated with the
induction of VEGF, facilitating the growth of independent tumour
vasculature [4]. Thus anti-angiogenic drugs, including the thalido-
mide derivative pomalidomide, protein kinase inhibitors such as
sunitinib and sorafenib, or anti-vascular endothelial growth factor
(anti-VEGF) reagents such as bevacizumab and cediranib, therefore
remain at the forefront of cancer investigations. Virtually all can-
cers are considered to have hypoxic regions though, with the more
aggressive tumours surviving hypoxic conditions especially well,
and hypoxia itself is linked to poor treatment success. An essentialresponse to hypoxia is apoptosis, but changes in gene expression
such as gain of function of BCL-2 or loss of BAX and BAK are sufﬁ-
cient to confer resistance in cancer cells [5]. The presence of hypox-
ia in conjunction with neovascularisation appears to be an
anomaly. Tumour vessels are however structurally and function-
ally abnormal [for example 6, 7] with microvascular disruption
and haemorrhaging leading to acidosis and hypoxia. The conse-
quent release of serum further promotes tumour cell proliferation
and survival. Furthermore, structural abnormalities in vessels con-
tribute to heterogeneity within a tumour and may ultimately inﬂu-
ence therapeutic responses to treatment [6,8,9].
Despite an increased understanding of tumour vascular biology,
progress towards translation of this new knowledge into effective
cancer therapeutics is generally disappointing. Each year 7.5 mil-
lion deaths are attributed to cancer worldwide. The combination
of anti-angiogenic treatments with chemotherapy or radiation
has produced marginally better outcomes than anti-angiogenics
alone [10] and in 2005 Jain proposed ‘‘normalisation’’ of tumour
vasculature, with judicious application of anti-vascular treatments
aimed at selectively removing only the abnormal vessels in order
to get more efﬁcient delivery of drugs and oxygen to the targeted
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produced limited beneﬁts and can in fact be harmful [11]. Unex-
pected toxicities have also emerged, including haemorrhage,
hypertension, gastrointestinal perforation, impaired wound heal-
ing and increased risk of thrombosis [12]. There is evidence too
that anti-angiogenic drug resistance can develop, for example
through upregulation of VEGF-C expression [13]. Furthermore, pa-
tients with malignant gliomas receiving maintenance through bev-
acizumab inevitably experience recurrent tumours that are
reported to be more aggressive with rebound oedema [14]. Whilst
removal of the vessels may lead to initial tumour regression, it is
treating a symptom, leaving the tumour (and surrounding tissue)
more hypoxic and the body less able to respond to the cancer, as
well as limiting further drug delivery and so contributing to ‘‘drug
resistance’’.
Gap junction channels have been implicated in lesion spread
following injury, and application of gap junction channel blockers
has been shown in a number of models to improve healing, in part
and of particular relevance here by preventing vascular disruption
and/or by restoring vascular integrity. In this review we shall re-
port the vascular changes that occur with acute and chronic
wounds and disease, and from our lessons learnt through connexin
channel regulation, apply this knowledge to tumour vessel biology.
Contrary to current opinion, these data suggest a need to protect,
maintain and/or restore cancer vasculature. Improved blood ﬂow
may then reduce tumour hypoxia, promoting survival of normal
cells, enabling the body’s immune system to better respond to
the tumour, and providing for improved delivery of cytotoxic drugs
and more effective radiation therapy.2. Connexin roles in vascular leak
Vascular disruption and vessel leak is not unique to cancer. It is
a common feature of acute injury and chronic injury and disease. It
is well established that even the blood brain barrier becomes leaky
following an insult such as ischemia or infection, enabling both
molecules and cells to easily migrate across the normally imper-
meable barrier. Gap junction channels play multiple roles after in-
jury, during wound healing, and in chronic wounds. Increased Cx43
expression often correlates with inﬂammatory responses [15–18]
although it may also play a moderating role in some cases [19].
Gap junction mediated lesion spread has been described in a num-
ber of models [20–22], and wound healing studies indicate that
down regulation of connexin expression, or gap junction channel
modulation, can reduce inﬂammation and scarring, and in surface
tissues increase the rate of epithelial recovery [15–17,23–26]. In
recent years we have become especially interested in gap junction
channel roles in microvascular leak and vessel die back that has
been reported in a number of models after wounding. A number
of connexin isoforms have been identiﬁed in the vascular wall
including Cx40, Cx37, Cx45 and Cx43. Cx43 and Cx45 are found
in smooth muscle cells with Cx40, Cx37 and Cx43 all reported in
endothelial cells [for review see 27]. Changes in the expression of
these connexins has been reported in diseases such atherosclerosis
and ischemia [27,28]. Increased Cx43 expression in particular
though has been consistently associated with endothelial cell re-
sponses to injury and disease. Interactions between leukocytes
and endothelial cells are said to be early events in both acute
and chronic inﬂammation, and in wound defence [29] although
the presence of an actual bridge remains controversial [30,31].
The means by which this occurs has historically been thought to
be mechanistic, involving changes in the expression of multiple
genes in the endothelial cells [25] that lead to increased permeabil-
ity and dysfunction, facilitating movement across the blood vessel
wall [31]. Tumour necrosis factor-a has been reported to play apart in causing such changes leading to an increase in vascular per-
meability, although other molecules such as VEGF may also play a
role. In addition, expression of the gap junction protein connexin43
(Cx43) is upregulated in both endothelium and inﬂammatory cells
and this is associated with macrophage inﬁltration and endothelial
cell activation [32]. Trans-endothelial inﬂammatory cell migration
can be reduced by the gap junction blockers octanol and 18a-glyc-
yrrhetinic acid in vitro [33]. In a speciﬁc example, mouse lungs in-
ﬂamed by intratracheal instillations of Pseudomonas aeruginosa
lipopolysaccharide (LPS) show upregulated levels of Cx43 in lung
alveoli [34] with parallel in vitro studies indicating that Cx43 reg-
ulates neutrophil adhesion to endothelial cells. In heterozygous
Cx43/+ mice, however, airway neutrophil counts were reduced
by over half, and conversely, neutrophil numbers increased in
LPS challenged mice expressing a modiﬁed Cx43 with higher chan-
nel conductivity. Instillation of the gap junction channel blocking
peptide Gap26 into the lungs reduced neutrophil transmigration
by 65%. Hence, neutrophil–endothelial cell adhesion has been in-
voked as the mechanism by which the inﬁltration of inﬂammatory
cells is regulated, but the mechanism involved may not be so
clearly deﬁned. In a virtually identical rat model of bacteraemia,
inanimate latex particles perfused into the inﬂamed lungs were
found clustered in a pattern similar to that of neutrophils during
pulmonary sepsis and there was a sevenfold increase in plasma
levels in the airspaces as a result of vascular leak [35]. These data
suggest that Cx43 is not so much playing a mechanistic role in
transendothelial migration, but rather a Cx43 mediated loss of vas-
cular integrity leaving the vessel wall permeable.
Such onset of endothelial dysfunction, plasma leak and haemor-
rhaging is also symptomatic of cerebral malaria [36–38]. Patients
infected with Plasmodium parasites who present with impaired
consciousness and cerebral malaria often exhibit retinal haemor-
rhaging, an indicator of poor prognosis, with autopsy revealing
petechial haemorrhaging in the brain. In experimental cerebral
malaria models, vascular leak and petechial haemorrhaging is the
major lethal event [36,37]. C57BL/6 mice infected with Plasmodium
berghei, succumb to cerebral malaria after 5–6 days and can be
scored for clinical signs of severe malaria. Systemic delivery of
Cx43 mimetic peptides by intraperitoneal injection appears to re-
duce or delay the vascular leak resulting from infection induced
vessel dysfunction. In a trial experiment, clinical scores showed a
signiﬁcant beneﬁt in using the mimetic peptides (P = 0.03). Results
indicated that treated animals were not succumbing to the infec-
tion as rapidly as controls, so providing a window of opportunity
for anti-malarial treatment, potentially extending it by up to 48 h
[39].
Following spinal cord injury also, speciﬁc down-regulation of
Cx43 with antisense oligodeoxynucleotides attenuates the recruit-
ment of neutrophils [15]. After cord injury, a marked elevation of
Cx43 expression is observed in the walls of small blood vessels
within the white matter accompanied by an acute phase starting
within 1–2 h that involves haemorrhage up to 4 mm either side
of the lesion (demonstrated with systemic delivery of ﬂuores-
cently-labelled albumin), inﬂammation and oedema. Suppression
of Cx43 upregulation using antisense oligodeoxynucleotides lim-
ited vascular leakage and reduced neutrophil recruitment ﬁvefold
[15], again suggesting a role for Cx43 in the pathogenesis of endo-
thelial cell dysfunction. This reduction in Cx43 protein subse-
quently led to a signiﬁcant improvement in locomotor ability.
Down regulation of Cx43 using antisense oligodeoxynucleotides
also attenuates recruitment of both neutrophils and macrophages
at skin wound sites [17,23,24].
In chronic inﬂammatory conditions, endothelial cell death is a
major feature. In vascular skin ulcers poor quality of arterial ﬂow
or a perturbed venous system is prevalent [40,41]. Post-mortem
analysis of human brain tissue from donors who had pathologically
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oinﬂammatory disorders) identiﬁed morphological changes to the
microvasculature indicating capillary dysfunction [42,43]. In
addition, Parkinson’s patients have high levels of cytokines in the
cerebrospinal ﬂuid, including the proinﬂammatory markers TNF-
a, IL-1b and IL-6 [44]; TNF-a and IL-1b in combination are known
to induce Cx43 expression, although that study was in dendritic
cells [45]. The presence of these cytokines, and T-cell inﬁltration,
supports the idea of a compromised blood brain barrier in neuro-
degenerative diseases and chronic inﬂammation.
Furthermore, evidence is mounting that it is speciﬁcally conn-
exin hemichannels that are playing a direct role in mediating loss
of endothelial cells and damaging the vascular wall. De Bock et al.
have reported that Cx43 mimetic peptides can prevent transendo-
thelial leak in vitro and in vivo induced by application of the inﬂam-
matory peptide bradykinin [46]. They concluded that, in contrast
to the loss of endothelial barrier function when gap junctions are
inhibited [47], inhibition of hemichannels appears to preserve bar-
rier function. Although they suggested that this effect was the re-
sult of indirectly modifying the tight junction barrier, it is more
likely that hemichannel opening under hypoxic or inﬂammatory
conditions leads directly to endothelial cell death. Opening of
Cx43 hemichannels is associated with ATP release that arises from
hypoxia [48] and hypoxia alone, is sufﬁcient to trigger Cx43 med-
iated endothelial cell loss in vitro [49,50]. This can be nicely dem-
onstrated using an in vitro endothelial cell protocol. Human
microvascular endothelial cells were made hypoxic by incubating
them in a 95% N2, 5% CO2 mixture for 3 h. Following hypoxia the
medium was replaced with complete media with either 0.1%
DMSO (no treatment), the nonspeciﬁc gap junction channel blocker
carbenoxolone, the nonspeciﬁc hemichannel blocker lanthanum
chloride, a hemichannel blocking Cx43 mimetic peptide or a con-
trol scrambled peptide. After incubation for a further 6 h a Trypan
Blue count of viable cells showed approximately 30% cell loss in
untreated or scramble control peptide treated cells, while gap
junction channel blockers provide almost total sparing (Fig. 1).
There is therefore considerable evidence that increased Cx43
expression can lead to compromised vascular integrity, and thatFig. 1. The number of viable endothelial cells in vitro is signiﬁcantly reduced after
3 h of hypoxic injury and 6 h reperfusion after no treatment or scrambled peptide
application. With carbenoxolone, lanthanum chloride (LaCl3) or Cx43 mimetic
peptide treatment (at a concentration sufﬁcient to block hemichannels but not to
uncouple gap junctions) the number of viable cells is signiﬁcantly higher than no
treatment. The number of viable cells is expressed as percentage of the control
without hypoxia. Stars denote statistical signiﬁcance using the Wilcoxon test when
compared to the control group or compared between groups in brackets at P < 0.05.this can include direct endothelial cell disruption in addition to
changes in the tight junction barrier or facilitated cell movement
across the vessel wall. The eye is an organ in which chronic disease
and wound healing processes can be observed directly in a manner
not possible in other organs or tissues. The following section de-
scribes speciﬁc examples in this organ.3. Chronic inﬂammatory disorders and trauma of the eye
Glaucoma occurs at all ages but increases with age, affecting
10% of adults over 70 years. Alterations in Cx43 levels have been
described using in vitro [16] and in vivo [51,52] models of optic
nerve disease. A potentially important consequence of Cx43 upreg-
ulation in glaucomatous eyes may be associated with a deﬁned role
in the maintenance of perivascular barriers that are weakened with
the disease. Patients with glaucoma exhibit vascular leakage on
ﬂuorescein angiography [53] and peripapillary chorioretinal atro-
phy is associated with areas of blood–retinal barrier breakdown
[54]. In addition, optic disc haemorrhages in glaucoma patients
may represent areas of perivascular barrier dysfunction at the edge
of the optic nerve head [55].
Age-related macular degeneration (AMD) is the leading cause of
irreversible visual impairment in people over the age of 60 years in
all developed nations. It affects the macula, an area of the retina
that provides for detailed vision [56]. Research has primarily fo-
cussed on degeneration of the retinal pigmented epithelium that
leads to irreversible degeneration of photoreceptors [57]. AMD is
however increasingly being recognised as a vascular disease with
blood vessel changes closely associated with pathogenesis and pro-
gress of the disease [58]. Along with retinal pigmented epithelium
degeneration, there is abnormal blood vessel growth through
Bruch’s membrane, eventually leading to haemorrhaging below
the macula of the retina and causing irreversible damage to the
photoreceptors and subsequent loss of vision [59,60]. This associ-
ated neovascularisation appears to be vessel growth (typical of
anywound healing situation) but occurringwithin an inﬂammatory
environment that results in vessel disruption and haemorrhaging.
Current AMD treatments primarily target these ‘‘abnormal’’ vessels
with an expectation that normal choriocapillaris will be largely
unaffected by anti-VEGF (such as bevacizumab and ranibizumab)
treatments. However, two year follow up studies indicate that this
is not the case, with increased use of anti-VEGF reagents correlating
with an increased incidence of new geographic AMD, an early stage
of the disease [61]. This suggests that in AMD the over use of anti-
angiogenic agents may lead to ischemic rebound. In both of these
chronic conditions, glaucoma and AMD, therefore, there are simi-
larities in the vessel bed with that of tumors, with vascular leakage
and areas of blood–brain (retina) barrier breakdown. It is of note
that in AMD blood vessel haemorrhaging is the more critical sign
of the disease, not the presence of the vessels per se.
The retina, like the brain and spinal cord, responds to ischae-
mia-reperfusion with both neurodegeneration and increased
vascular permeability taking place [62–64]. In a retinal ischae-
mia-reperfusion study vascular integrity of retinal vessels was
shown to be compromised as early as 1 h following ischaemia-
reperfusion and continued up to the 24 h time point [49], with
the onset of vascular leak coinciding with increased Cx43 expres-
sion. The subsequent opening of connexin hemichannels causes
uptake of water resulting in cell swelling [65] with hypoxia in-
duced endothelial cell loss after retinal ischaemia likely owing to
an inability to osmoregulate [49]. Signiﬁcantly, the vessel leak
(Fig. 2A) correlates with reduced blood ﬂow (indicated by areas
devoid of systemic dye perfusion) and regions of vascular disrup-
tion (with vessels that are leaky, tortuous, dilated and which
have blind endings and trans-endothelial gaps) (Fig. 2B). This
Fig. 2. There are a number of common features between the vasculature in acute injuries and those described in cancer. In A vessel haemorrhaging is present within 1–2 h of
reperfusion in a retinal ischemia-reperfusion model, seen here using systemic Evans Blue dye perfusion to show the vessels and leakage from them. The arrows point to areas
of vessel haemorrhage and the circles indicate regions where dye has not penetrated indicating little or no blood ﬂow. Labelling of endothelial cells in these regions with
isolectin-B4, seen in B, shows that vascular integrity has been lost with blind endings to vessels (arrow), clumped endothelial cells indicating vessel wall disruption (asterisks)
and single lines of endothelium indicating trans-endothelial gaps in the opposing vessel wall (arrow head). Scale bar = 500 lm.
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look more closely at tumour vasculature. The terms used above
to describe these vessels are commonly used to describe tumour
neovascularisation [see for example 66, 67] and there appears,
therefore, to be little difference between vascular morphology in
a tumour and that which occurs after acute ischemia in the retina.
It is of note that systemic delivery of Cx43 mimetic peptides via a
single intraperitoneal injection, at a ﬁnal concentration designed to
block hemichannels but not to uncouple gap junctions, reduced the
vascular leak after ischemia in the retina to just 14% of that of con-
trols at the peak 4 h post-injury time point (which dampened
inﬂammation and subsequently resulted in a signiﬁcant reduction
in retinal ganglion cell or neuron loss).
In a ﬁnal example, non-healing epithelial wounds and chronic
ulcers are a signiﬁcant health challenge. Wound oedema and arte-
rial insufﬁciency are known to be causative factors in chronic
wounds yet established therapies and attempts to promote angio-
genesis have failed to achieve consistent beneﬁts, in line with stud-
ies suggesting that there are anti-angiogenic factors mediating
vessel regression in wounds that override any pro-angiogenic sig-
nals present [68]. The anti-angiogenic factor in a wound environ-
ment may be gap junction channel related. Ormonde et al [69]
reported the use of gap junction Cx43 speciﬁc antisense oligode-
oxynucleotides to treat ﬁve patients with severe, non-healing ocu-
lar chemical or thermal burns that had been unresponsive to
established best practice clinical management for seven days to
eight weeks prior to treatment. Inﬂammation and changes in the
vascular bed of the ocular surface were readily discernible using
a slit lamp and in all cases the most salient feature following treat-
ment was reduction in inﬂammation, recovery of the vascular bed
and limbal reperfusion. In all ﬁve patients full ocular surface resto-
ration was achieved. These data suggest that ongoing vascular
endothelial cell death, rather than an inherent lack of angiogenesis,
may be the overriding factor in chronic wounds. Fig. 3A shows the
eye of a patient 5 days after receiving a severe alkali burn. The eye
was red and inﬂamed, but slit lamp examination revealed that
there was no blood ﬂow and the limbal region of the cornea was
ischaemic. In this example, an amniotic membrane has been
stitched over the eye to promote healing but this failed to have
any effect. Fig. 3B shows the same eye 24 h after the application
of Cx43 speciﬁc antisense oligodeoxynucleotides injected beneath
the amniotic membrane at day 9 post injury. Vascular structure is
now evident with limbal reperfusion and re-epithelialisationstarting across the cornea. We were struck by the similarity in
the appearance of a non-healing ocular burn and the appearance
of, for example, a pancreatic tumour. Both are red and inﬂamed
and show signs of vascular haemorrhage but in the eye it is also
possible to see that blood is stagnant with little blood ﬂow. We
set out to see if this also applied to a tumour. Fig. 3C shows a
HCT116 human colon tumour removed from a nude mouse eleven
days after subcutaneous implantation of cancer cells. The tumour
shows signs of vascular haemorrhage but lack of Evans Blue dye
uptake, injected systemically into the animal 10 min before tu-
mour removal, indicates that there is little or no blood ﬂow to
the tumour. In the eye burns, we were able to restore blood ﬂow
and promote healing by transiently down regulating connexin
expression [69] so we set out to restore ﬂow in the HCT116 tumour
model, in this instance using intraperitoneal injection of our conn-
exin speciﬁc, hemichannel blocking mimetic peptide that had
proved effective in the retinal stroke model above [49,70].
Fig. 3D shows a representative HCT116 xenograft following intra-
peritoneal connexin peptide injection twice daily between days
four and eleven. The tumour shows little sign of haemorrhaging
and Evans Blue dye uptake suggests there had to be patent blood
ﬂow into the tumour.
4. The paradigm shift
The observations made in the preceding section led us to con-
sider more carefully the established view that neovascularisation
feeds a tumour and promotes tumour growth.
It was in 1971 that Folkman [1] proposed that solid tumour
growth was more dependent upon new vessel growth than previ-
ously appreciated. Work by Tannock [71,72] had for example
shown that mitotic indices reduced with distance from a blood
vessel and Folkman’s own group had identiﬁed a tumour derived
angiogenesis factor [1]. Although none of these early studies dem-
onstrated actual increased blood ﬂow, tumour growth is still
thought to require the formation of new blood vessels [reviewed
for example by 2] and much new drug development such as cedira-
nib [8], VEGF blockade combinations [3] or chromenes [73] re-
mains focused on removing the abnormal tumour vasculature.
Yet anti-angiogenic treatments have in general had limited effects
[11]. In 2005 Jain proposed a more measured approach to ‘‘normal-
ise’’ the vascular bed through selective removal of abnormal
vessels. He noted that anti-angiogenic agents could transiently
Fig. 3. There are similarities to the vessel bed in non-healing chemical burnt human eyes and solid tumours. A shows the eye of a patient 5 days after receiving a severe alkali
burn [see 69 for details]. The eye is red and inﬂamed with extensive haemorrhaging but there was no blood ﬂow as ascertained by viewing the eye with a slit lamp. In this
patient an amniotic membrane has been stitched over the eye to promote healing but this failed to have any effect. B shows the same eye 24 h after the application of Cx43
speciﬁc antisense oligodeoxynucleotides injected beneath the amniotic membrane at day 9 post injury. Vascular structure is now evident and slit lamp examination showed
blood ﬂow through the vessels. For comparison, C shows a subcutaneous HCT116 human colon cancer cell tumour removed from a mouse eleven days after injection of the
cells. The tumour shows signs of vascular haemorrhage in several places (arrowheads) but there is little evidence of Evans Blue dye uptake (administered by intraperitoneal
injection 10 min before euthanasia) indicating limited external blood supply to the tumour and a situation analogous to that seen in A. D shows a similar HCT116 tumour but
the animal was injected twice daily between days four and eleven with a connexin speciﬁc, hemichannel blocking Cx43 mimetic peptide. There is little sign of haemorrhaging
and Evans Blue dye uptake suggests patent blood ﬂow into the tumour, comparable to the treated eye seen in B. Scale bar = 5 mm.
Fig. 4. Montage images of sections taken through HCT116 human colon tumours
removed from mice eleven days after injecting cells. Each section has been imaged
for Evans Blue dye (red) injected intraperitoneally 10 min before euthanasia and
used to indicate blood ﬂow, and labelled with isolectin-B4 (green) to mark
endothelial cells and DAPI (blue) to mark cell nuclei. A shows a tumour from an
animal injected twice daily from days 4 to 11 with a scrambled control peptide.
Although there are endothelial cells present around the outer edge of the tumour
there are only a few patches of Evans Blue dye within the tumour. There is little
correlation between endothelial cells and dye uptake. B shows a tumour from an
animal injected twice daily from days 4 to 11 with a connexin speciﬁc, hemichannel
blocking Cx43 mimetic peptide. There is strong evidence for vascular integrity
within the tumour with Evans Blue dye correlating with endothelial cells, and the
pattern of dye uptake suggesting patent blood ﬂow into the tumour. Scale
bar = 1 mm.
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immune cells and it has been suggested that visualisation of angi-
ogenesis may enable more appropriate selection of patients for
drug treatments [2].
Anti-angiogenesis therefore remains a primary target despite
apparent inconsistencies that exist. Firstly, there is Folkman’s pro-
posal that neovascularisation feeds a tumour yet cancers are acidic
and hypoxic indicating poor blood supply. Corollaries are that pa-
tients with maintenance of bevacizumab experience recurrent tu-
mours that are reported to be more aggressive with rebound
oedema [14] and radiation therapy has reduced efﬁcacy because
the tumours lack oxygen [74]. Secondly, neovascularisation should
aid drug delivery yet this remains a challenge. Brain tumours are
inherently difﬁcult to treat in part owing to the blood brain barrier
[75] but tumour vessels are leaky, and the most common brain
tumour, cerebral metastases, is characterised by oedema and
subarachnoid haemorrhage [76]. Thirdly, patients receiving
anti-angiogenic cediranib treatments that led to increased blood
ﬂow had 6–9 months longer survival than those who did not gain
increased blood ﬂow [8]. Fourthly, cancer vessels are often com-
pared with development angiogenesis, yet the tumour microenvi-
ronment leads to abnormal endothelial cells and micro-vessels
[7]. There are angiogenic signals, but growth is poorly regulated
and the endothelial cells are dysfunctional.
It is possible to address these anomalies by shifting the emphasis
from anti-neovascularisation, to preservation and restoration of
vascular integrity to improve blood ﬂow. As we have described
above, there are a number of common features between the vascu-
lature in cancers and that seen in acute and chronicwounds, includ-
ing hypoxia and/or inﬂammation induced vessel haemorrhage and
ischemic rebound with anti-VEGF therapies. As in wounds such as
the non healing ocular burns [69], an alternative approach to cancer
treatment might therefore be to restore and maintain vascular
integrity. As noted above, Jain has reported that the judicious use
of anti-angiogenic cediranib treatments can actually lead toincreased blood ﬂow, with such patients having 6–9 months longer
survival than those who did not gain ﬂow [8]. In our own laborato-
ries, the preliminary experiment with HCT116 human colon xeno-
grafts in mice showed improved vascular integrity and Evans Blue
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daily intraperitoneal injections with connexin mimetic peptide
(N-terminal acetylated and C-terminal amidated peptide5 – see
[70]) for seven days, compared to untreated controls/xenografts
(Fig. 4). Peptide treated tumours were 55% smaller (mean weight)
than scrambled control treated peptides although statistical signif-
icance was not reached in this pilot study.
It is possible that there are other means to protect or restore tu-
mour vasculature. Pannexin channel regulation may, like connexin
channel regulation, have a therapeutic role in stroke and CNS trau-
ma. To date such a role appears to be primarily around the regula-
tion of ATP release [77,78], but reduced ATP release is associated
with reduced inﬂammation and less secondary expansion of CNS
lesions [78]. Pannexin channels may also have an important role
in ATP release throughout the vascular network [79], and may
potentially therefore also have beneﬁcial roles in vessel mainte-
nance. It is important to be aware of potential pitfalls, including
effects of channel blockers on other putative connexin roles in
tumours. Connexins have for example been proposed to be acting
as tumour suppressors [see for example 80] and Cx32 is said to
enhance endothelial cell migration and tube formation [81]. Fur-
thermore, vessel co-option whereby tumour cells migrate along
pre-existing vessels [82] may be compounded with improved
vascular integrity. Conventional dogma though would also suggest
that improved vessel ﬂow would correlate with increased tumour
growth and this is not observed [8].5. Conclusion
It is 40 years since neovascularisation was identiﬁed as a key
target for the treatment of cancers but progress has been disap-
pointing. We propose instead that the problem to be addressed
in cancer is not the presence or growth of vessels per se, but the
vascular disruption and haemorrhage that follows as a result of
the tumour microenvironment. The consequence is the release of
serum and factors that promote tumour cell proliferation and hy-
poxia that supports cancer cell growth whilst preventing a normal
immune or regulatory response from occurring. In this article we
have discussed the connexin mediated loss of vascular integrity re-
ported in a number of injury and disease examples, and then in the
section on chronic inﬂammatory disorders and trauma of the eye
highlighted speciﬁc similarities in vessel structure and function
after injury and in chronic disease with those seen in tumours. This
analysis of both acute and chronic wound models and disease, and
the application of gap junction channel regulators to promote heal-
ing in many of those models, led us to conclude that it may not be
growth of new vessels that promotes tumour growth, but rather
vascular haemorrhage and disruption as a result of the inﬂamma-
tory tumour environment into which those new vessels are grow-
ing. Protection of blood ﬂow should reduce tumour hypoxia,
promote survival of normal cells, enable the body’s immune sys-
tem to better respond to the tumour, enable improved delivery
of cytotoxic drugs or anti-tumour cells, and increase the effective-
ness of radiation therapy. There may well be a number of ways to
achieve this, but we propose that gap junction channel modulation
could be one effective way to do so.Acknowledgements
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